Format

Send to

Choose Destination
J Parkinsons Dis. 2015;5(4):947-59. doi: 10.3233/JPD-150662.

Tracking Parkinson's: Study Design and Baseline Patient Data.

Collaborators (215)

Grosset D, Bajaj N, Sugathapala L, Burn D, Graham A, Bathgate D, Bland R, Worth P, Mamutse G, Amar K, Walker R, Raw J, Carroll C, Clarke CE, Hemsley Z, Fackrell R, Roberts H, Guptha S, Nath U, Barker R, Counsell C, Sheridan R, Silverdale M, Sharma J, Piccini P, Hindle J, Arianayagam S, Ellis S, Ward T, Lennox G, Carson M, Sveinbjornsdottir S, Boothman B, Paviour D, Misbahuddin A, Schrag A, Athey R, Sarda P, Steiger M, Dhakam Z, Kock N, Molloy S, O'Neill M, Stern J, Capps E, Critchley P, Foltynie T, George J, Bandmann O, Harper G, Andrews T, Woodward W, Whone A, Borland C, Wilson M, Adenwala Y, Tidswell P, Chaudhuri R, Watt A, Church A, Morris H, Hu M, Kamath S, Adler B, Barber S, De Pablo-Fernandez E, Sophia R, Agarwal V, Alderton L, Amor K, Andrew A, Arif S, Bennett J, Birchall K, Birt J, Blachford K, Brooke J, Brown A, Brown P, Brugaletta C, Bryden N, Burrows M, Butler S, Cable S, Callaghan R, Canovas L, Carey G, Cattarall L, Clipsham K, Colwell W, Cowen Z, Cox C, Craw S, Creaser-Smith A, Croucher Y, Daniel S, De Pietro A, Dellafera D, Dodds S, Donaldson A, Donaldson D, Dougherty A, Downes C, Dube S, Dwornik W, Edwards C, Ekins E, Fernandes R, Foale C, Forbes H, Ford S, Frost J, Fuller T, Gallagher L, Gentle R, Gethin L, Gilford J, Gray C, Gunter E, Hall S, Hamilton C, Hare M, Henderson A, Hetherington V, Higgins R, Higham A, Hill L, Hodgson K, Humphries R, Hurlstone S, Hursey A, Inniss R, James R, Johnson E, Joyce R, Kefalopoulou Z, Kelly M, Korley M, Lehn A, Levy S, Lithgo K, Long C, Lyle A, Lynn H, MacKinnon L, Makahamadze C, Mahan T, Marks N, Marrinan S, Marshall M, Martin-Forbes P, Massey I, McBrearty C, McEntee J, McNichol A, Mills D, Morgan S, Mullan D, Murphy T, Newman J, O'Connell H, O'Donnell A, O'Donnell D, O'Reilly C, Olanrewaju O, Oughton E, Owen C, Painter S, Palfreeman S, Paterson P, Perkins L, Pilcher A, Powell K, Price C, Rachman P, Renton L, Rickett J, Rizos A, Roberts T, Roche M, Roopun R, Roussakis AA, Rowland R, Saunders G, Sequeira C, Shields S, Simmons D, Snape C, Stickley J, Strong L, Sunderland C, Sutherland S, Temple N, Thomson E, Trimmer M, Tuazon J, Tyrrell E, Visentin E, Vandor C, Vernon N, Verstraelen N, Visick M, Walsh H, Walsh S, Ward K, Watson A, Watt A, Whelan E, Williams J, Williams M, Williams S, Wilson B, Witherington K, Woodcock R, Wyatt L.

Author information

1
Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.
2
School of Social and Community Medicine, University of Bristol, Bristol, UK.
3
Institute of Neuroscience, University of Newcastle, Newcastle upon Tyne, UK.
4
Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
5
Department of Neurology, Queen's Medical Centre, Nottingham, UK.
6
Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, Cambridge, UK.
7
Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
8
Reta Lila Weston Laboratories, Dept of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
9
Department of Clinical Neuroscience, UCL Institute of Neurology, London, UK.
10
Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.

Abstract

BACKGROUND:

There is wide variation in the phenotypic expression of Parkinson's disease (PD), which is driven by both genetic and epidemiological influences.

OBJECTIVES:

To define and explain variation in the clinical phenotype of PD, in relation to genotypic variation.

METHODS:

Tracking Parkinson's is a multicentre prospective longitudinal epidemiologic and biomarker study of PD. Patients attending specialist clinics in the United Kingdom with recent onset (<3.5 years) and young onset (diagnosed <50 years of age) PD were enrolled. Motor, non-motor and quality of life assessments were performed using validated scales. Cases are followed up 6 monthly up to 4.5 years for recent onset PD, and up to 1 year for young onset PD. We present here baseline clinical data from this large and demographically representative cohort.

RESULTS:

2247 PD cases were recruited (1987 recent onset, 260 young onset). Recent onset cases had a mean (standard deviation, SD) age of 67.6 years (9.3) at study entry, 65.7% males, with disease duration 1.3 years (0.9), MDS-UPDRS 3 scores 22.9 (12.3), LEDD 295 mg/day (211) and PDQ-8 score 5.9 (4.8). Young onset cases were 53.5 years old (7.8) at study entry, 66.9% male, with disease duration 10.2 years (6.7), MDS-UPDRS 3 scores 27.4 (15.3), LEDD 926 mg/day (567) and PDQ-8 score 11.6 (6.1).

CONCLUSIONS:

We have established a large clinical PD cohort, consisting of young onset and recent onset cases, which is designed to evaluate variation in clinical expression, in relation to genetic influences, and which offers a platform for future imaging and biomarker research.

KEYWORDS:

Parkinson’s disease; genotype; heterogeneity; phenotype

PMID:
26485428
PMCID:
PMC4927877
DOI:
10.3233/JPD-150662
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center